- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
DLBCL | Clinical
ctDNA is a Possible Prognostic Tool for Predicting DLBCL Outcomes
September 12, 2022
A presentation at ESMO 2022 explains the use of circulating tumor DNA as a tool which can predict outcomes for patients with diffuse large B-cell lymphoma.
Orelabrutinib Added to R-CHOP Reveals Promising Efficacy in non-GCB DLBCL
September 12, 2022
The combination of orelabrutinib plus the R-CHOP regimen revealed a positive overall response rate of 86.4% when given to patients with non-germinal center B cell-like diffuse large B-cell lymphoma.
Roundtable Discussion: Barriers to CAR T-Cell Therapy for DLBCL Lead to Debate About Targeted Therapy
August 27, 2022
During a Targeted Oncology case-based roundtable event, Pallawi Torka, MD, discussed with participants when to consider a patient for chimeric antigen receptor T-cell therapy and what alternative treatments to use for a patient with relapsed/refractory diffuse large B-cell lymphoma.
Improving Tolerability of Polatuzumab + BR for R/R DLBCL
August 26, 2022
Ian W. Flinn, MD, PhD, discusses his experience using the combination of polatuzumab vedotin-piiq plus bendamustine and rituximab for patients with relapsed/refractory diffuse large B-cell lymphoma.
Patients’ Frailty Status Significantly Associated With 1-Year Mortality in DLBCL
August 25, 2022
In a study, a correlation between frailty status and death at 1 year was identified in patients with diffuse large B-cell lymphoma.
Critical Unmet Needs in DLBCL
August 19, 2022
Ian Flinn, MD, PhD, describes some of the important unmet needs of DLBCL, particularly in R/R DLBCL, and shares his hopes for the future of treatment.
An Oncologist’s Perspective on Future Treatment Options for the Profiled Patient and Targeted Treatment Approaches in R/R DLBCL
August 19, 2022
An oncologist shares which treatment regimen he would recommend next for this patient with DLBCL who experienced two disease relapses and reflects on how CD19- and CD79b-targeted therapies have impacted patient outcomes in the field.
Available Treatment Options in DLBCL with 2 or More Relapses
August 19, 2022
Dr Ian Flinn explains the available treatment options for patients with DLBCL who experience 2 or more relapses, and the situations in which he would use each regimen.
Second-Line Treatment Approaches for R/R DLBCL
August 19, 2022
An expert provides his perspective on the first- and second-line treatment approaches in the patient case and comments on the patient’s likely prognosis.
Introduction: A 68-Year-Old Man with Diffuse Large B-Cell Lymphoma
August 19, 2022
Ian Flinn, MD, PhD, presents the case of a 68-year-old man with diffuse large B-cell lymphoma (DLBCL) and 2 relapses after complete disease remission.